ALNY (Alnylam Pharmaceuticals) Research & Development: $1,420 Mil (TTM As of Mar. 2026)


ALNY Alnylam Pharmaceuticals Inc ALNY
74 GF Score
Price $294.94
GF Value $513.74
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals Research & Development?

Alnylam Pharmaceuticals ALNY +0.30% 74 Research & Development is $1,420 Mil as of Mar. 2026. GuruFocus rates ALNY with a GF Score™ of 74/100 and a GF Value™ of $513.74 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alnylam Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was $365 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $1,420 Mil.

Alnylam Pharmaceuticals  (NAS:ALNY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alnylam Pharmaceuticals Research & Development Related Terms

Alnylam Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Research & Development Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 792.16 883.02 1,004.42 1,126.23 1,319.78

Alnylam Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265.12 323.62 358.81 372.22 364.87
ALNY
74GF Score
Alnylam Pharmaceuticals Inc ALNY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,420 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1,420 Mil mean?
Alnylam Pharmaceuticals (ALNY) has a Research & Development of $1,420 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Research & Development too high?
Alnylam Pharmaceuticals' current Research & Development is $1,420 Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Research & Development compare to RVMD and ONC?
Alnylam Pharmaceuticals' Research & Development of $1,420 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Research & Development is $1,420 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (ALNY) is currently considered Significantly Undervalued. The stock's GF Value™ is $513.74, compared to a current price of $294.94 — trading 42.6% below its estimated fair value. The current Research & Development is $1,420 Mil. Alnylam Pharmaceuticals' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alnylam Pharmaceuticals (ALNY), the current Research & Development is $1,420 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (ALNY) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $294.94 is trading 42.6% below its estimated GF Value™ of $513.74. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ALNY:

  • Research & Development: $1,420 Mil
  • GF Value™: $513.74 vs. price of $294.94 (42.6% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the ALNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
74GF Score

Get the complete analysis for ALNY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$294.94
Price
$513.74
GF Value